The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.
The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike BlakeSunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.
Treatment of HIV infections typically involves daily administration of a combination of drugs - such as Gilead's Biktarvy and ViiV Healthcare's Triumeq - that suppress replication of the virus. Gilead was working to have its drug, which will be given in addition to existing therapies, available in January, the company's vice president of HIV Clinical Development, Jared Baeten, told Reuters in an interview before the approval.
The approval bulks up Gilead's HIV portfolio, which generated sales of $16.32 billion in 2021 out of total revenue of $27.3 billion.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA weighs new guidance about risks of LASIK eye surgeryThe FDA wants LASIK patients to know more about the risks of the popular eye surgery, but doctors say the agency
Consulte Mais informação »
FDA Commissioner Urges Parents Not to Stockpile Children's Flu Medications Amid ShortagesThe surge in flu cases and COVID-19 infections, along with elevated levels of RSV, has caused elevated demand for children's over-the-counter cold and flu medications — but the FDA commissioner is urging parents to resist buying more than what they need
Consulte Mais informação »
Horse food recalled after 45 deaths, FDA saysA snack for horses is being recalled after 45 horses died from eating it, according to the FDA.
Consulte Mais informação »
U.S. FDA approves Roche's COVID-19 antibodyRoche Holding AG said on Wednesday the U.S. Food and Drug Administration (FDA) had approved its monoclonal antibody for treating COVID-19 in hospitalized adult patients.
Consulte Mais informação »
Roche gets full FDA approval for COVID-19 treatmentRoche Holding AG undefined said late Wednesday that the Food and Drug Administration formally approved its monoclonal antibody for adults who have been...
Consulte Mais informação »